Viewing Study NCT01977534



Ignite Creation Date: 2024-05-06 @ 2:09 AM
Last Modification Date: 2024-10-26 @ 11:14 AM
Study NCT ID: NCT01977534
Status: COMPLETED
Last Update Posted: 2018-12-17
First Post: 2013-10-18

Brief Title: To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold BVS System in Patients With de Novo Lesions in Previously Untreated Vessels
Sponsor: Abbott Medical Devices
Organization: Abbott Medical Devices

Study Overview

Official Title: A Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb BVS
Status: COMPLETED
Status Verified Date: 2018-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ABSORB UK
Brief Summary: The purpose of this study is to determine the safety and clinical outcomes of the Absorb BVS for daily use in patients with de novo lesions in previously untreated vessels
Detailed Description: ABSORB UK registry is a prospective single arm post-market registry designed to

Provide ongoing post-market surveillance for documentation of safety and clinical outcomes of the Absorb Everolimus Eluting BVS System in daily percutaneous coronary intervention PCI practice per Instructions for Use IFU on-label use
Collect additional information eg acute success to evaluate handling and implantation of Absorb BVS by physicians under a wide range of commercial use conditions and following routine clinical practice

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None